• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.

    4/22/26 9:47:24 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FATE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 10)


    FATE THERAPEUTICS INC

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    31189P102

    (CUSIP Number)
    Josh Garcia
    Redmile Group, LLC, 900 Larkspur Landing Circle, Suite 270
    Larkspur, CA, 94939
    (415) 489-9980

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/20/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    31189P102


    1 Name of reporting person

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    18,229,078.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    18,229,078.00
    11Aggregate amount beneficially owned by each reporting person

    18,229,078.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.9 %
    14Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:
    (1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"), including RedCo II Offshore SPV LLC ("RedCo II SPV"). (2) The information in Item 5(a) relating to the shares of common stock, $0.001 par value per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated by reference herein. (3) Percent of class calculated based on: (a) 116,263,459 shares of Common Stock outstanding on February 19, 2026, as disclosed in the Issuer's annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 26, 2026 (the "Form 10-K"), plus (b) 152,227 shares of Common Stock issuable upon the exercise of the Options (as defined in Item 5(a) below), plus (c) 5,192,574 shares of Common Stock issuable upon either the exercise of the Pre-Funded Warrants held by the Redmile Funds, or the conversion on a one-for-five basis of the shares of the Class A Preferred Stock held by the Redmile Funds, which due to the Warrant Beneficial Ownership Limitation and the Preferred Beneficial Ownership Limitation, as applicable (each as described in Item 5(a) below), is the maximum number of shares that could be issued upon exercise of the Pre-Funded Warrants or conversion of the Class A Preferred Stock.


    SCHEDULE 13D

    CUSIP Number(s):
    31189P102


    1 Name of reporting person

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    18,229,078.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    18,229,078.00
    11Aggregate amount beneficially owned by each reporting person

    18,229,078.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.9 %
    14Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:
    (1) The source of funds was working capital of the Redmile Funds, including RedCo II SPV. (2) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green is incorporated by reference herein. (3) Percent of class calculated based on: (a) 116,263,459 shares of Common Stock outstanding on February 19, 2026, as disclosed in the Issuer's Form 10-K, plus (b) 152,227 shares of Common Stock issuable upon the exercise of the Options (as defined in Item 5(a) below), plus (c) 5,192,574 shares of Common Stock issuable upon either the exercise of the Pre-Funded Warrants held by the Redmile Funds, or the conversion on a one-for-five basis of the shares of the Class A Preferred Stock held by the Redmile Funds, which due to the Warrant Beneficial Ownership Limitation and the Preferred Beneficial Ownership Limitation, as applicable (each as described in Item 5(a) below), is the maximum number of shares that could be issued upon exercise of the Pre-Funded Warrants or conversion of the Class A Preferred Stock.


    SCHEDULE 13D

    CUSIP Number(s):
    31189P102


    1 Name of reporting person

    RedCo II Offshore SPV LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    10,144,307.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    10,144,307.00
    11Aggregate amount beneficially owned by each reporting person

    10,144,307.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.5 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    (1) The information in Item 5(a) relating to the shares of Common Stock that are or may be deemed beneficially owned by RedCo II SPV is incorporated by reference herein. (2) Percent of class calculated based on: (a) 116,263,459 shares of Common Stock outstanding on February 19, 2026, as disclosed in the Issuer's Form 10-K, plus (b) 2,778,091 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants held by RedCo II SPV, plus (c) 609,655 shares of Common Stock issuable upon the conversion on a one-for-five basis of the shares of the Class A Preferred Stock held by RedCo II SPV.


    SCHEDULE 13D

    CUSIP Number(s):
    31189P102


    1 Name of reporting person

    RedCo II Master Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    (1) Following the internal reorganization among certain Redmile Funds described in Item 3 below, RedCo II Master Fund, L.P. beneficially owned no shares of the Issuer's Common Stock.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    FATE THERAPEUTICS INC
    (c)Address of Issuer's Principal Executive Offices:

    12278 Scripps Summit Drive, San Diego, CALIFORNIA , 92131.
    Item 2.Identity and Background
    (a)
    This amendment No. 10 to Schedule 13D (this "Amendment No. 10") amends and supplements the Schedule 13D filed with the SEC on August 2, 2018, as previously amended and supplemented by amendment No. 1 to the Schedule 13D filed with the SEC on September 27, 2018, amendment No. 2 to the Schedule 13D filed with the SEC on September 17, 2019, amendment No. 3 to the Schedule 13D filed with the SEC on June 18, 2020, amendment No. 4 to the Schedule 13D filed with the SEC on January 12, 2021, amendment No. 5 to the Schedule 13D filed with the SEC on April 19, 2023, amendment No. 6 to the Schedule 13D filed with the SEC on December 26, 2023, amendment No. 7 to the Schedule 13D filed with the SEC on March 25, 2024, amendment No. 8 to the Schedule 13D filed with the SEC on December 26, 2024 and amendment No. 9 to the Schedule 13D filed with the SEC on July 3, 2025 (collectively, the "Prior Schedule 13D"), by Redmile Group, LLC, a Delaware limited liability company ("Redmile"), Jeremy C. Green, a citizen of the United Kingdom, and, from amendment No. 5 until this Amendment No. 10, RedCo II Master Fund, L.P., a Cayman Island exempted limited partnership, in each case, relating to the common stock, $0.001 par value per share (the "Common Stock"), of Fate Therapeutics, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used but not defined in this Amendment No. 10 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 10, the Prior Schedule 13D is unchanged.
    (b)
    Item 2(b) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green: c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo II Offshore SPV LLC: c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 RedCo II Master Fund, L.P.: c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
    (c)
    Item 2(c) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile Group, LLC: investment manager/adviser to certain private investment vehicles Jeremy C. Green: managing member of Redmile RedCo II Offshore SPV LLC: private investment fund RedCo II Master Fund, L.P.: private investment fund
    (d)
    During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Item 2(f) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom RedCo II Offshore SPV LLC: Cayman Islands RedCo II Master Fund, L.P.: Cayman Islands
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Prior Schedule 13D is hereby amended and supplemented by adding the following paragraph immediately after the last paragraph of Item 3: On April 20, 2026, in connection with an internal reorganization of RedCo II Master Fund, L.P. ("RedCo II Master"), a private investment vehicle managed by Redmile Group, LLC ("Redmile"), Redco II Master contributed all of its securities of the Issuer pro rata and in kind, for no consideration, to its two wholly-owned subsidiaries (collectively, the "SPVs"), including RedCo II Offshore SPV LLC ("RedCo II SPV"), which are also managed by Redmile. The securities consisted of: (a) 8,977,624 shares of Common Stock, par value $0.001 per share (the "Common Stock"), (b) Pre-Funded Warrants to purchase 3,691,324 shares of Common Stock, (c) 162,013 shares of Class A Preferred Stock (which, based on the one-for-five conversion ratio, are convertible into 609,655 shares of Common Stock), and (d) notional shares of cash-settled swaps representing the economic equivalent of 266,280 shares of the Common Stock. As a result of the internal reorganization, (i) RedCo II Master ceased to have voting or dispositive power over any of the Issuer's securities and, therefore, is no longer a beneficial owner of more than 5% of the Issuer's Common Stock and will be dissolved, and (ii) RedCo II SPV became a beneficial owner of more than 5% of the Common Stock. Accordingly, this Amendment No. 10 serves as an exit filing for RedCo II Master and as an initial filing for RedCo II SPV. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Prior Schedule 13D is hereby amended and restated in its entirety as follows: The aggregate amount of shares of Common Stock that may be deemed beneficially owned by the Reporting Persons includes the following: (i) 353,233 shares of Common Stock held by Redmile Capital Offshore II Master Fund, Ltd., (ii) 146,127 shares of Common Stock held by Redmile Strategic Trading Sub, Ltd., (iii) 1,253,227 shares of Common Stock held by Redmile Strategic Long Only Trading Sub, Ltd., (iv) 6,756,561 shares of Common Stock held by RedCo II Offshore SPV LLC, (v) 2,221,063 shares of Common Stock held by RedCo II Onshore SPV LLC, (vi) 1,931,216 shares of Common Stock held by Redmile Biopharma Investments I, L.P., (vii) 107,103 shares of Common Stock held by RedCo I, L.P., and (viii) 104,416 shares of Common Stock held by RM Special Holdings 8, LLC. Redmile is the investment manager/adviser to each of the Redmile Funds and, in such capacity, exercises voting and investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the managing member of Redmile and also may be deemed to be the beneficial owner of these shares. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The Reporting Persons may also be deemed to beneficially own: (i) 11,331 shares of Common Stock pursuant to certain restricted stock units that have vested or will vest within 60 days of the date of this filing, and (ii) 152,227 shares of Common Stock subject to options to purchase shares of Common Stock that are exercisable within 60 days of the date of this filing (the "Options"). The restricted stock units and Options were granted to Michael S. Lee, a managing director of Redmile, in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds the restricted stock units and Options as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the restricted stock units and Options to Redmile. Redmile and Mr. Green each disclaim beneficial ownership of the restricted stock units and Options, except to the extent of its or his pecuniary interest in the shares subject to such restricted stock units and Options, if any, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities any purpose. Subject to the Preferred Beneficial Ownership Blocker (as defined below), the Reporting Persons may also be deemed to beneficially own shares of Common Stock issuable upon conversion of the following: (i) 194,884 shares of the Issuer's Class A Preferred Stock held by Redmile Capital Fund, LP, (ii) 176,110 shares of Class A Preferred Stock held by Redmile Capital Offshore Master Fund, Ltd., (iii) 1,687,110 shares of Class A Preferred Stock held by Redmile Capital Offshore II Master Fund, Ltd., (iv) 162,426 shares of Class A Preferred Stock held by Redmile Strategic Trading Sub, Ltd., (v) 342,422 shares of Class A Preferred Stock held by Redmile Biopharma Investments I, L.P., (vi) 121,931 shares of Class A Preferred Stock held by RedCo II Offshore SPV LLC, (vii) 40,082 shares of Class A Preferred Stock held by RedCo II Onshore SPV LLC, and (viii) 30,121 shares of Class A Preferred Stock held by RM Special Holdings 8, LLC. The Class A Preferred Stock is convertible into shares of Common Stock on a one-for-five basis. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the "Certificate of Designation"), the Issuer may not effect any conversion of the Class A Preferred Stock, and a holder of the Class A Preferred Stock does not have the right to convert any portion of the Class A Preferred Stock held by such holder, to the extent that, after giving effect to the attempted conversion set forth in a notice of conversion, such holder, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for purposes of Section 13(d) or Section 16 of the Act, and the applicable regulations of the SEC, including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Preferred Beneficial Ownership Limitation (the "Preferred Beneficial Ownership Blocker"). The "Preferred Beneficial Ownership Limitation" is 14.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. Subject to the Warrant Beneficial Ownership Blocker (as defined below), the Reporting Persons may also be deemed to beneficially own shares of Common Stock issuable upon exercise of pre-funded warrants (the "Pre-Funded Warrants") to purchase (i) 202,350 shares of Common Stock held by Redmile Strategic Trading Sub, Ltd., (ii) 2,778,091 shares of Common Stock held by RedCo II Offshore SPV LLC, and (iii) 913,233 shares of Common Stock held by RedCo II Onshore SPV LLC. The Pre-Funded Warrants are exercisable at a price of $0.001 per share. Pursuant to the terms of the Pre-Funded Warrants, the Issuer shall not effect any exercise of, and a holder of a Pre-Funded Warrant shall not be entitled to exercise, the Pre-Funded Warrant held by such holder for a number of shares of Common Stock in excess of the number of shares of Common Stock which, upon giving effect or immediately prior to such exercise, would cause (x) the aggregate number of shares of Common Stock beneficially owned by such holder, such holder's affiliates and any other persons whose beneficial ownership of Common Stock would be aggregated with such holder's for purposes of Section 13(d) of the Act to exceed the Maximum Percentage (as defined below) of the total number of issued and outstanding shares of Common Stock following such exercise, or (y) the combined voting power of the securities of the Issuer beneficially owned by such holder and its affiliates and any other persons whose beneficial ownership of Common Stock would be aggregated with such holder's for purposes of Section 13(d) of the Act to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise (the "Warrant Beneficial Ownership Blocker"). The "Maximum Percentage" is 14.99%, which percentage may be changed to up to 19.99% at a holder's election upon at least 61 days' notice to the Issuer. Under the Warrant Beneficial Ownership Limitation and the Preferred Beneficial Ownership Limitation, as applicable, the maximum amount of Common Stock that could be issued to the Redmile Funds in the aggregate upon exercise of the Pre-Funded Warrants and/or conversion of the Class A Preferred Stock is 5,192,574 shares, which includes (i) the 2,778,091 shares of Common Stock that could be issued upon exercise of the Pre-Funded Warrants directly held by RedCo II SPV and (ii) the 609,655 shares of Common Stock that could be issued upon conversion on the 121,931 shares of Class A Preferred stock directly held by RedCo II SPV. For purposes of this Schedule 13D, the percent of class for Redmile and Jeremy Green was calculated based on: (a) 116,263,459 shares of Common Stock outstanding on February 19, 2026, as disclosed in the Issuer's annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 26, 2026 (the "Form 10-K"), plus (b) 152,227 shares of Common Stock issuable upon the exercise of the Options, plus (c) 5,192,574 shares of Common Stock issuable upon either the exercise of the Pre-Funded Warrants held by the Redmile Funds, or the conversion on a one-for-five basis of the shares of the Class A Preferred Stock held by the Redmile Funds, which due to the Warrant Beneficial Ownership Limitation and the Preferred Beneficial Ownership Limitation, as applicable, is the maximum number of shares that could be issued upon exercise of the Pre-Funded Warrants or conversion of the Class A Preferred Stock. For purposes of this Schedule 13D, the percent of class for RedCo II SPV was calculated based on: (a) 116,263,459 shares of Common Stock outstanding on February 19, 2026, as disclosed in the Issuer's Form 10-K, plus (b) 2,778,091 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants held by RedCo II SPV, plus (c) 609,655 shares of Common Stock issuable upon the conversion on a one-for-five basis of the shares of the Class A Preferred Stock held by RedCo II SPV.
    (b)
    Redmile Group, LLC: (1) Sole Voting Power: 0 (2) Shared Voting Power: 18,229,078 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 18,229,078 Jeremy C. Green: (1) Sole Voting Power: 0 (2) Shared Voting Power: 18,229,078 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 18,229,078 RedCo II Offshore SPV LLC: (1) Sole Voting Power: 0 (2) Shared Voting Power: 10,144,307 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 10,144,307 RedCo II Master Fund, L.P.: (1) Sole Voting Power: 0 (2) Shared Voting Power: 0 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 0
    (c)
    Other than the internal reorganization described in Item 3, there have been no transactions in the Issuer's securities by the reporting persons in the past 60 days.
    (e)
    On April 20, 2026, RedCo II Master ceased to be a beneficial owner of more than 5% of the Issuer's Common Stock.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The paragraph under the heading "Swap Novation" is hereby added after the last paragraph in Item 6 of the Prior Schedule 13D: Swap Novation In connection with the internal reorganization described in Item 3, RedCo II Master novated the swap agreements to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:04/22/2026
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:04/22/2026
     
    RedCo II Offshore SPV LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of Redmile Group, LLC, its manager
    Date:04/22/2026
     
    RedCo II Master Fund, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of RedCo II (GP), LLC, its General Partner
    Date:04/22/2026
    Get the next $FATE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FATE

    DatePrice TargetRatingAnalyst
    10/31/2025$5.00Neutral → Buy
    H.C. Wainwright
    10/27/2025$7.00Neutral → Outperform
    Wedbush
    11/18/2024Underperform → Neutral
    BofA Securities
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    3/27/2023$6.00Equal Weight
    Wells Fargo
    1/24/2023$115.00 → $7.00Buy → Neutral
    H.C. Wainwright
    1/6/2023$20.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    1/6/2023$71.00 → $12.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/26/24 9:00:15 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/28/23 9:30:16 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Redmile Group, Llc

    4/A - FATE THERAPEUTICS INC (0001434316) (Issuer)

    4/23/26 9:00:13 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Redmile Group, Llc

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    4/22/26 9:51:32 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Tahl Cindy was granted 100,000 shares, increasing direct ownership by 26% to 487,081 units (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    1/16/26 4:03:32 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $FATE
    SEC Filings

    View All

    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

    SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company's next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026. The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edit

    4/16/26 9:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

    SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026. 25th Annual Needham Virtual Healthcare Conference Location: Virtual Date: April 14th   Bank of America Healthcare Conference 2026 Location: Encore at the Wynn - Las Vegas, NV         Date: May 13th H.C. Wainwright 4th Annual BioConnect Investor Conference  Location: Nasdaq

    4/9/26 9:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering in

    4/2/26 4:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.

    SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    4/22/26 9:47:24 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fate Therapeutics Inc.

    SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    3/26/26 6:21:12 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Fate Therapeutics Inc.

    10-K - FATE THERAPEUTICS INC (0001434316) (Filer)

    2/26/26 9:07:51 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fate Therapeutics from Neutral to Buy and set a new price target of $5.00

    10/31/25 8:14:08 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by Wedbush with a new price target

    Wedbush upgraded Fate Therapeutics from Neutral to Outperform and set a new price target of $7.00

    10/27/25 8:29:46 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by BofA Securities

    BofA Securities upgraded Fate Therapeutics from Underperform to Neutral

    11/18/24 3:46:41 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    11/14/24 7:50:18 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    10/25/24 9:37:07 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

    SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    3/25/24 5:15:23 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Financials

    Live finance-specific insights

    View All

    Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

    First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

    5/9/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

    SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

    5/6/24 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

    CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

    2/26/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Leadership Updates

    Live Leadership Updates

    View All

    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer

    SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus. "We are excited to wel

    10/14/25 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Announces Leadership Transition

    Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

    11/29/24 1:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care